SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 119.21 |
| Enterprise Value ($M) | 123.31 |
| Book Value ($M) | -0.88 |
| Book Value / Share | -0.05 |
| Price / Book | -136.09 |
| NCAV ($M) | -17.82 |
| NCAV / Share | -1.03 |
| Price / NCAV | -6.69 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.53 |
| Return on Assets (ROA) | -0.67 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.30 |
| Current Ratio | 0.51 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 9.64 |
| Assets | 26.59 |
| Liabilities | 27.47 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 25.19 |
| Operating Income | -6.99 |
| Net Income | -12.91 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -6.68 |
| Cash from Investing | -3.03 |
| Cash from Financing | 6.78 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Rakib Vivien | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 861 | 3,081 | 27.95 | |
| 6,461 | 17,588 | 36.74 | |
| 1,123 | 5,361 | 20.95 | |
| 1,908 | 16,275 | 11.72 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AVDL – Avadel Pharmaceuticals plc | AXSM – Axsome Therapeutics, Inc. |
| BCAB – BioAtla, Inc. | BTMD – biote Corp. |
| CADL – Candel Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io